Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Raw Materials (2016 - 2018)

Anika Therapeutics (ANIK) has disclosed Raw Materials for 8 consecutive years, with $13.2 million as the latest value for Q3 2018.

  • On a quarterly basis, Raw Materials rose 68.31% to $13.2 million in Q3 2018 year-over-year; TTM through Sep 2018 was $13.2 million, a 68.31% increase, with the full-year FY2017 number at $11.3 million, up 91.98% from a year prior.
  • Raw Materials was $13.2 million for Q3 2018 at Anika Therapeutics, up from $12.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $13.2 million in Q3 2018 to a low of $4.9 million in Q3 2015.
  • A 5-year average of $7.4 million and a median of $6.3 million in 2017 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: dropped 28.96% in 2015, then surged 100.13% in 2018.
  • Anika Therapeutics' Raw Materials stood at $6.2 million in 2014, then decreased by 6.2% to $5.8 million in 2015, then increased by 1.8% to $5.9 million in 2016, then skyrocketed by 91.98% to $11.3 million in 2017, then rose by 17.22% to $13.2 million in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Raw Materials are $13.2 million (Q3 2018), $12.6 million (Q2 2018), and $10.1 million (Q1 2018).